11-108244873-C-T

Variant summary

Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM5_SupportingPVS1PM2_SupportingPM3

This summary comes from the ClinGen Evidence Repository: The c.748C>T (p.Arg250*) variant in ATM is a nonsense variant predicted to cause a premature stop codon in biologically-relevant-exon leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism. This alteration results in a termination codon upstream of the most C-terminus pathogenic alteration (ATM p.Arg3047*), as classified by the HBOP VCEP, and is expected to be more deleterious. This variant has been detected in numerous individuals with Ataxia-Telangiectasia (PMIDs: 10330348, 12552559, 20840352, 21778326, 22006793, 26896185, 30816533, 31611883). The highest population minor allele frequency in gnomAD v2.1.1 0.00003 (1/34560) which meets the PM2 threshold of n≤1 alleles when sub-population frequency is >0.00001 (PM2_Supporting met). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant ATM-related cancer predisposition and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP. (PVS1, PM5_Supporting, PM3_VeryStrong, PM2_Supporting) LINK:https://erepo.genome.network/evrepo/ui/classification/CA336868/MONDO:0700270/020

Frequency

Genomes: not found (cov: 31)
Exomes 𝑓: 0.0000068 ( 0 hom. )

Consequence

ATM
NM_000051.4 stop_gained

Scores

2
4
1

Clinical Significance

Pathogenic reviewed by expert panel P:19

Conservation

PhyloP100: 2.20
Variant links:
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 12 ACMG points.

PVS1
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.
PM3
For more information check the summary or visit ClinGen Evidence Repository.
PM5
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ATMNM_000051.4 linkc.748C>T p.Arg250* stop_gained Exon 7 of 63 ENST00000675843.1 NP_000042.3 Q13315A0A024R3C7

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ATMENST00000675843.1 linkc.748C>T p.Arg250* stop_gained Exon 7 of 63 NM_000051.4 ENSP00000501606.1 Q13315

Frequencies

GnomAD3 genomes
Cov.:
31
GnomAD3 exomes
AF:
0.00000398
AC:
1
AN:
251002
Hom.:
0
AF XY:
0.00000737
AC XY:
1
AN XY:
135654
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000684
AC:
10
AN:
1461624
Hom.:
0
Cov.:
32
AF XY:
0.00000825
AC XY:
6
AN XY:
727120
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000252
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000540
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
Cov.:
31
ExAC
AF:
0.00000824
AC:
1

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:19
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Ataxia-telangiectasia syndrome Pathogenic:4
Jul 02, 2018
Mendelics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Dec 26, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change creates a premature translational stop signal (p.Arg250*) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is present in population databases (rs772821016, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with ataxia-telangiectasia and/or breast cancer (PMID: 10330348, 12552559, 22006793, 28724667). ClinVar contains an entry for this variant (Variation ID: 216024). Studies have shown that this premature translational stop signal is associated with inconclusive levels of altered splicing (internal data). For these reasons, this variant has been classified as Pathogenic. -

Sep 07, 2016
Counsyl
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 10, 2021
Natera, Inc.
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Pathogenic:4
Dec 13, 2022
Color Diagnostics, LLC DBA Color Health
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant changes 1 nucleotide in exon 7 of the ATM gene, creating a premature translation stop signal. In addition, RNA extracted from carrier-derived lymphoblastoid cells have shown the skipping of exon 7 (also known as exon 9 in the literature; PMID: 10330348, 22006793). Both aberrant transcripts are expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with breast cancer (PMID: 28724667, 33471991) and in the compound heterozygous state in individuals affected with ataxia-telangiectasia (PMID: 10330348, 12552559, 22006793). This variant has also been identified in 1/251002 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -

Jan 26, 2018
Academic Department of Medical Genetics, University of Cambridge
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: research

Application of AMCG guidelines 2015. Used other ClinVar submission evidence where relevant. Loss of heterozygosity in tumours or immunohistochemistry abnormalities considered functional evidence of pathogenicity. -

Feb 10, 2022
Sema4, Sema4
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: curation

- -

Apr 05, 2024
Ambry Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.R250* pathogenic mutation (also known as c.748C>T), located in coding exon 6 of the ATM gene, results from a C to T substitution at nucleotide position 748. This changes the amino acid from an arginine to a stop codon within coding exon 6. This mutation has been reported in a cohort of 7657 BRCA1/2-negative Chinese breast cancer patients (Yang Z et al. Breast Cancer Res Treat, 2019 Apr;174:639-647) and in a cohort of 460 individuals from 440 families with at least two primary tumors by age 60 years or at least three by 70 years (Whitworth J et al. Am J Hum Genet, 2018 07;103:3-18). This mutation has been detected in numerous patients with ataxia-telangiectasia (A-T) in conjunction with another pathogenic ATM mutation (Teraoka SN et al. Am. J. Hum. Genet. 1999 Jun;64:1617-31; Buzin CH et al. Hum. Mutat. 2003 Feb;21:123-31; Keimling M et al. FASEB J. 2011 Nov;25:3849-60; Nakamura K et al. Hum. Mutat. 2012 Jan;33:198-208). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -

Familial cancer of breast Pathogenic:3
Jan 31, 2024
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change creates a premature translational stop signal (p.Arg250*) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant Not observed at a significant frequency in large population cohorts (gnomAD). This premature translational stop signal has been observed in individual(s) with ataxia-telangiectasia and/or breast cancer (PMID: 30816533, 25525159, 12552559, 22006793, 19022408, 10330348, 20840352, 27479817, 21778326, 29909963, 22763152, 30607632, 32521533, 28724667, 32427313, 35664542, 31472684, 34954471, 30697212, 35158934). ClinVar contains an entry for this variant (Variation ID: 216024).This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay For these reasons, this variant has been classified as Pathogenic. -

Sep 05, 2023
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jan 11, 2024
Myriad Genetics, Inc.
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -

ATM-related cancer predisposition Pathogenic:2
Nov 26, 2024
ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel, ClinGen
Significance: Pathogenic
Review Status: reviewed by expert panel
Collection Method: curation

The c.748C>T (p.Arg250*) variant in ATM is a nonsense variant predicted to cause a premature stop codon in biologically-relevant-exon leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism. This alteration results in a termination codon upstream of the most C-terminus pathogenic alteration (ATM p.Arg3047*), as classified by the HBOP VCEP, and is expected to be more deleterious. This variant has been detected in numerous individuals with Ataxia-Telangiectasia (PMIDs: 10330348, 12552559, 20840352, 21778326, 22006793, 26896185, 30816533, 31611883). The highest population minor allele frequency in gnomAD v2.1.1 0.00003 (1/34560) which meets the PM2 threshold of n≤1 alleles when sub-population frequency is >0.00001 (PM2_Supporting met). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant ATM-related cancer predisposition and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP. (PVS1, PM5_Supporting, PM3_VeryStrong, PM2_Supporting) -

Aug 16, 2021
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Pathogenic:2
Jun 21, 2022
GeneDx
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30816533, 25525159, 12552559, 22006793, 19022408, 10330348, 20840352, 27479817, 21778326, 29909963, 22763152, 30607632, 32521533, 28724667, 32427313, 35664542, 31472684, 34954471, 30697212, 35158934) -

Oct 01, 2022
CeGaT Center for Human Genetics Tuebingen
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

ATM: PVS1, PM2 -

Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Pathogenic:1
Apr 04, 2024
Fulgent Genetics, Fulgent Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Gastric cancer Pathogenic:1
Jul 01, 2021
Laboratory for Genotyping Development, RIKEN
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: research

- -

ATM-related disorder Pathogenic:1
Mar 13, 2024
PreventionGenetics, part of Exact Sciences
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

The ATM c.748C>T variant is predicted to result in premature protein termination (p.Arg250*). This variant has been reported as compound heterozygous in individuals with ataxia-telangiectasia and as heterozygous in individuals with breast cancer (Buzin et al 2003. PubMed ID: 12552559; Cao et al 2019. PubMed ID: 30816533; Sun et al 2017. PubMed ID: 28724667; Yang et al. 2019. PubMed ID: 30607632). This variant is reported in 0.0029%% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/216024/). Nonsense variants in ATM are expected to be pathogenic. This variant is interpreted as pathogenic. -

Malignant tumor of breast Pathogenic:1
Mar 15, 2021
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: ATM c.748C>T (p.Arg250X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. At least one publication reports experimental evidence that this variant affects mRNA splicing (Teraoka_1999). The variant allele was found at a frequency of 7.6e-06 in 261978 control chromosomes. c.748C>T has been reported in the literature in individuals affected with Ataxia-Telangiectasia or Breast Cancer (Teraoka_1999, Decker_2017). These data indicate that the variant is likely to be associated with disease. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.53
D
BayesDel_noAF
Pathogenic
0.60
CADD
Pathogenic
35
DANN
Uncertain
1.0
Eigen
Uncertain
0.48
Eigen_PC
Uncertain
0.28
FATHMM_MKL
Uncertain
0.89
D
Vest4
0.93, 0.92
GERP RS
3.4
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs772821016; hg19: chr11-108115600; COSMIC: COSV53725394; COSMIC: COSV53725394; API